ESMO 2020 | ESMO highlights: 705MO study in GU cancer

Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the 705MO study (NCT03606174), which evaluated the combination of sitravatinib with nivolumab in checkpoint inhibitor naïve, platinum-experienced patients with advanced or metastatic urothelial carcinoma (UC). The study found positive clinical activity with a manageable side effect profile. Dr Msaouel also briefly highlights a practice-changing study which saw very impressive improvement in overall survival (OS) using Avelumab switch maintenance therapy in advanced urothelial cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).